Table 2.
Results from the quality assessment of the interactive, web-based clinical decision tools for personalized breast cancer treatment using the ‘International Patient Decision Aids Standards instrument (IPDASi) checklist.
| Tool | Information about options (8) | Outcome probabilities (8) | Clarifying values (4) | Decision guidance (2) | Development process (6) | Using evidence (5) | Disclosure and transparency (2) | Plain language (1) | Total (36) |
|---|---|---|---|---|---|---|---|---|---|
| Neoadjuvant Therapy | |||||||||
| Breast Cancer Nomogram to Predict Positive SLNs, after Neoadjuvant Chemotherapy [34,35] | 3 | 3 | 0 | 1 | 1 | 2 | 1 | 1 | 12 |
| Breast Cancer Nomogram to Predict Positive SLNs, without Neoadjuvant Chemotherapy [36,37] | 3 | 3 | 0 | 1 | 1 | 2 | 1 | 1 | 12 |
| Breast Cancer Nomogram to Predict Additional Positive Non-SLN, without Neoadjuvant Chemotherapy [38,39] | 3 | 3 | 0 | 1 | 1 | 2 | 1 | 1 | 12 |
| Breast Cancer Non-SLN Nomogram Calculator, with Neoadjuvant Chemotherapy [40,41] | 3 | 3 | 0 | 1 | 1 | 4 | 1 | 1 | 14 |
| Response to Neoadjuvant Chemotherapy [42] | 3 | 6 | 0 | 1 | 2 | 0 | 0 | 0 | 12 |
| Residual Cancer Burden Calculator [43] |
2 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 7 |
| Chemotherapy Response Calculator [44] | 3 | 4 | 0 | 1 | 2 | 0 | 0 | 0 | 10 |
| Radiation Therapy | |||||||||
| Breast Cancer Nomogram to Predict Benefit of Radiation for Older Patients who have undergone Breast Conserving Surgery [45,46] | 4 | 6 | 0 | 1 | 1 | 4 | 2 | 0 | 18 |
| IBTR! Version 2.0 [47] | 4 | 6 | 0 | 1 | 1 | 4 | 2 | 0 | 18 |
| Surgery/Adjuvant Treatment | |||||||||
| BTxChoice [48] | 5 | 6 | 0 | 1 | 1 | 4 | 2 | 0 | 19 |
| Age Gap Decision Tool: Primary Endocrine Therapy with and without Surgery [49] | 7 | 6 | 1 | 2 | 3 | 5 | 2 | 0 | 26 |
| Age Gap Decision Tool: Surgery with and without chemotherapy [50] | 7 | 6 | 1 | 2 | 3 | 5 | 2 | 0 | 26 |
| INFLUENCE [51,52] | 6 | 6 | 0 | 1 | 2 | 4 | 2 | 0 | 21 |
| Breastconservation.com [53,54] | 4 | 3 | 0 | 1 | 1 | 4 | 2 | 0 | 15 |
| PREDICT [56] | 6 | 6 | 0 | 1 | 2 | 5 | 2 | 0 | 22 |
| CancerMath: Therapy calculator [57] | 6 | 6 | 0 | 1 | 1 | 4 | 2 | 0 | 20 |
| CancerMath: Nipple involvement calculator [57] | 2 | 1 | 0 | 1 | 1 | 4 | 2 | 0 | 11 |
| Nottingham Prognostic Index [6,61] | 3 | 4 | 0 | 1 | 1 | 3 | 2 | 0 | 14 |
| Adverse Effects | |||||||||
| BRA Score [62] | 4 | 6 | 0 | 1 | 2 | 3 | 2 | 0 | 18 |
| Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer [63,64] | 4 | 4 | 0 | 1 | 1 | 3 | 2 | 0 | 15 |
Information about options: The tool describes the health condition, options available, natural course of the condition, and compares positive/negative features of each option.
Outcome probabilities: The tool provides information about the outcome probabilities for each option, specifies the defined reference class, event rates, and time period over which the outcomes apply, compares probabilities across the same time periods, provides information about uncertainty, and provides more than one way to view the probability.
Clarifying values: The tool describes features of options to help patients imagine what it is like to experience physical, psychological, and social effects.
Decision guidance: The tool provides a step-by-step way to decide and includes tools for discussion with practitioner.
Development process: The tool (or associated paper) mentions the development process including finding out what health professionals/patients need to prepare, whether the tool has been field-tested with professionals/patients, and any expert views.
Using evidence: The tool (or associated paper) describes how research evidence was selected or synthesized, provides a publication rate, and proposes update policy.
Disclosure and transparency: The tool (or associated technical documentation) provides information about funding used and includes author/developer credentials.
Plain Language: The tool (or associated paper) reports readability levels using available scales.